Ocugen, the Healthcare sector company, was revisited by a Wall Street analyst on May 8. Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on the stock and has a $12.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Whitney Ijem has given his Buy rating due to a combination of factors including a compelling efficacy signal in Ocugen’s gene therapy programs and a substantial unmet need in Stargardt disease and geographic atrophy. Feedback from key opinion leaders, such as Dr. Regillo, supports the view that meaningful reductions in atrophic lesion growth and a focus on early intervention could translate into clinically important benefits for patients, especially adolescents and younger adults.
In addition, Ijem views subretinal delivery as an acceptable and precedented procedure, reducing concerns around the practicality of Ocugen’s approach, even in older GA patients. The emerging competitive landscape, while active, still leaves room for differentiated, gene-based solutions, and the analyst believes Ocugen’s data to date justify continued development with attractive risk‑reward, supporting a Buy rating with an unchanged $12 price target.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.